Keryx Biopharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Keryx Biopharmaceuticals (Boston, MA): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $147.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Boston, MA |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 100.0% |
| Primary Portfolio LOE Date | 2030-01-01 |
| 2024 CMS Total Public Spend | $147.1M |
| 2024 Medicare Part D Spend | $131.5M |
| 2024 Medicaid Spend | $15.6M |
| California HCAI SB 17 Filings | 4 WAC filings (max 22.7% 2-yr change) |